Clinical Trials Browser

OTHER × tanezumab × Clear all

NCT04163419 2024-03-13

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

Phase 2 Active not recruiting

Schwannomatosis, Neurilemmoma, Hereditary Sensory and Autonomic Neuropathies, Pain